Company: AGIO
Filing Date: 2025-03-05
Form Type: S-8
Source: 0001193125-25-047359
Chunk: 1

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-03-05
Form: S-8
Chunk 1
---
 pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the
“Securities Act”).

Item 2. Registrant Information and Employee Plan Annual Information.

The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plans
covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the
Commission, are incorporated in this registration statement by reference:

(a) the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 as filed with the Commission on February 13, 2025;

(b) the information included in our definitive proxy statement on Schedule 14A for the 2024 Annual Meeting of Stockholders, as filed with the Commission on April 26, 2024, to the extent incorporated by reference into Part III of the Annual Report on Form 10-K for the fiscal
year ended December 31, 2023;

(c) the registrant’s Current Report on Form 8-K as filed with the
Commission on February 13, 2025; and

(d) the description of the registrant’s common stock contained in the registrant’s registration statement on Form 8-A filed under the Exchange Act on July
19, 2013, as the description therein has been updated and superseded by the description of the registrant’s capital stock contained in Exhibit 4.2 to the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Commission on February 23, 2023, and including any amendments and reports filed
for the purpose of updating such description.

All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been